fda semaglutide warning november 2025 warns Novo Nordisk over unreported Ozempic and Wegovy side effects Novo Nordisk expands patient access

16.9-47% of patients met the NICE composite endpoint (weight reduction of 3% or greater and HbA1c reduction of 1% or greater)

It is a clinically proven treatment that helps adults with obesity lose weight while also reducing the risk of cardiovascular events in patients who also have heart disease. 1 What Are the Legal and Market Implications

It can be, especially for those who respond well to GLP-1 medications and want a daily alternative to injections

However, with the change in dosage form can come some sticker shock a common hangover when seeking innovative solutions

Women of reproductive potential should be counseled about these risks and should use effective contraception during treatment